| 0.1831 -0.016 (-7.9%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94  |
1-year : | 1.4 |
| Resists | First : | 0.8 |
Second : | 1.2 |
| Pivot price | 0.46 |
|||
| Supports | First : | 0.17 |
Second : | 0.14 |
| MAs | MA(5) : | 0.21 |
MA(20) : | 0.58 |
| MA(100) : | 0.92 |
MA(250) : | 1.06 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.2 |
D(3) : | 2.4 |
| RSI | RSI(14): 13.8 |
|||
| 52-week | High : | 2.18 | Low : | 0.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CMND ] has closed above bottom band by 21.0%. Bollinger Bands are 290.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.22 - 0.22 | 0.22 - 0.22 |
| Low: | 0.17 - 0.17 | 0.17 - 0.17 |
| Close: | 0.18 - 0.18 | 0.18 - 0.19 |
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Thu, 20 Nov 2025
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site - The Manila Times
Mon, 17 Nov 2025
Clearmind Medicine Inc. Files Israeli Patent Application for Innovative Depression Therapy Combining MEAI and PEA - Quiver Quantitative
Thu, 13 Nov 2025
Clearmind Medicine receives approval for AUD clinical trial site - Investing.com
Thu, 13 Nov 2025
Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On? - Benzinga
Mon, 10 Nov 2025
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder Treatment Targeting $20 Billion Market - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 258 (K) |
| Shares Short P.Month | 300 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -59.7 % |
| Return on Equity (ttm) | -178.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | 0.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|